What's Happening?
Alto Neuroscience announced topline data from its Phase 2 proof-of-concept study of ALTO-101 for cognitive impairment associated with schizophrenia. The study did not achieve statistical significance on primary endpoints but showed directional improvements
in certain EEG measures. Alto has developed a modified-release formulation of ALTO-101 and plans to explore partnering opportunities. The company will prioritize its lead program, ALTO-207, for treatment-resistant depression, with a Phase 2b trial set to begin in the first half of 2026.
Why It's Important?
The mixed results of the ALTO-101 study highlight the challenges in developing treatments for cognitive impairment in schizophrenia. However, the potential of the modified-release formulation and the focus on ALTO-207 for treatment-resistant depression could position Alto as a leader in precision psychiatry. Successful development of ALTO-207 could provide a new treatment option for patients with limited alternatives, potentially improving outcomes in mental health care. Alto's strategic focus on its most promising programs reflects a commitment to advancing innovative therapies in neuropsychiatry.
